Cranbury, New Jersey, USA – [Date] – Crystal Pharmatech Inc. ("Crystal Pharmatech") and Divamics Inc. ("Divamics") today announced a strategic collaboration to integrate AI-aided drug discovery with world-leading crystal form, preformulation, and formulation development technologies. This partnership aims to provide end-to-end support from molecular design to clinical supply, accelerating timelines and improving the success rate for innovative drug programs.
Amid the rising costs and extended timelines in drug R&D, the collaboration targets two critical stages of the development process: intelligent molecule design and downstream pharmaceutical developability.
Divamics applies proprietary artificial intelligence (AI), quantum chemical computation, and molecular dynamics simulation technologies to optimize the design of novel drug molecules. Its platform rapidly generates active, developable molecular structures, significantly shortening discovery cycles and reducing early-stage costs. Applicable across small molecules, peptides, antibodies, PROTACs, and enzymes, Divamics has already advanced two partnered assets to Phase III clinical trials.
Crystal Pharmatech is globally recognized as a world leader in crystal form screening and selection, preformulation studies, and formulation development. With robust enabling technologies, Crystal Pharmatech improves both developability and bioavailability of drug candidates—facilitating their efficient progression into clinical trials and commercialization. Its services include Mol2Med™ developability assessment, solid form screening (polymorphs, salts, co-crystals), crystallization process development, pre-formulation studies, formulation development and GMP manufacturing for Phase I–III clinical trials and commercial supply.
The partnership is anchored in a synergistic “AI + Experimental” model—referring specifically to AI-aided drug discovery by Divamics followed by Crystal Pharmatech’s experimental preformulation and formulation development services.
This integrated model addresses the critical gap between AI-driven PCC (preclinical candidate) selection and downstream pharmaceutical development—ensuring that promising molecules can be effectively formulated and manufactured into viable drug products suitable for clinical use.
“Our collaboration with Crystal Pharmatech represents the ideal fusion of AI-based design and pharmaceutical development,” said Dr. John Zheng, Founder and CEO of Divamics. “By applying our proprietary AI platform to rationally design and optimize drug candidates, and then leveraging Crystal’s unmatched expertise in solid-state and formulation sciences, we can deliver a unified, efficient, and scalable solution for global pharma partners.”
Dr. Alex M. Chen, Co-founder, Chairman, and CEO of Crystal Pharmatech, commented, “Divamics’ advanced AI platform dramatically enhances the front end of drug discovery. At Crystal Pharmatech, we bring deep enabling technologies to improve both developability and bioavailability, ensuring that PCCs are not only potent but truly suitable for clinical development. Together, we are bridging a long-standing gap and accelerating the delivery of new medicines to patients.”
Crystal Pharmatech is a global leader in solid-state and formulation science, offering end-to-end drug development solutions from preclinical candidate selection to clinical supply. With operations in the United States, Canada, and China, the company supports pharmaceutical and biotech partners worldwide with deep technical expertise and flexible service models.
Renowned for its excellence in crystal form screening and selection, preformulation, and formulation development, Crystal Pharmatech helps optimize both developability and bioavailability across diverse drug modalities. Its integrated services span Mol2Med™ developability assessment, solid-form screening, crystallization process development, formulation development, and GMP manufacturing for Phase I–III clinical trials and commercialization.
Whether advancing a preclinical candidate (PCC) to first-in-human studies or resolving formulation challenges in clinical-stage programs, Crystal Pharmatech is a trusted partner for solving complex crystal form and formulation problems with speed and precision.
With a scientific team averaging 20 years of experience, the company has supported over 1,000 clients, enabling development of more than 2,000 preclinical compounds. Its multi-site presence across North America and Asia provides clients with strategic flexibility and consistent, high-quality service across regions.
Divamics is a global biotechnology innovator leveraging AI, quantum mechanics, and molecular dynamics to transform drug discovery. Our proprietary platform integrates multi-scale simulations and machine learning to deliver end-to-end solutions for target modeling, druggability assessment, and drug design/optimization across small molecules, peptides, and undruggable targets. Recognized with top-tier industry certifications and endorsed by Nobel Laureate scientists, we partner with 40+ biopharma leaders to advance 70+ drug pipelines. The platform accelerates discovery timelines by advancing 30 molecules to pre-clinical candidate (PCC) stage within 6-12 months, effectively addressing the critical challenges of cost, speed, and success rates in traditional R&D. Two collaborative programs have reached Phase III clinical trials, demonstrating our capability to drive high-impact outcomes in global drug development.
